NCT00602446 · OUTCOME

Reduction in Liver Iron Concentration After Study Drug

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant · Source last updated 2017-12-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: milligrams/gram
Interval / dispersion: Standard Deviation
Time frame: 6 Months

What was measured

Efficacy as measured by reduction in liver iron concentration (LIC) after 6 months of the study drug compared to baseline (LIC at baseline minus LIC at 6 months). This shows the mean reduction for the 3 subjects treated in this study.

Analysis population: All patients included in count.

Groups in this outcome

Deferasirox Treated

Includes patients that were treated with deferasirox for 6 months.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Deferasirox Treated	3

Reported measurements

Source class 1

Values in milligrams/gram · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Deferasirox Treated	5.6	4.8	Not reported	Not reported	Not reported

Complete source fields

anticipated Posting Date

2010-03

classes

categories
measurements
group Id
OG000
spread
4.8
value
5.6

denoms

counts
group Id
OG000
value
3
units
Participants

description

dispersion Type

Standard Deviation

groups

description
Includes patients that were treated with deferasirox for 6 months.
id
OG000
title
Deferasirox Treated

param Type

MEAN

population Description

All patients included in count.

reporting Status

POSTED

time Frame

6 Months

title

Reduction in Liver Iron Concentration After Study Drug

type

SECONDARY

unit Of Measure

milligrams/gram

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice